SAN DIEGO, CA – Victoria Yatsula, Product Manager from IntelliCyt Corporation, to speak at GTCbio’s 5th Assay and Drug Discovery Technologies on Sept. 20-21, 2010 in San Diego, CA.
Victoria Yatsula will give a presentation on “Multiplexed Cell-Based Screening Assays by High-Throughput Flow Cytometry” at the 5th Assay and Drug Discovery Technologies Conference to be held this year in San Diego, CA Sept. 20-21, 2010 by GTCbio. This presentation will cover innovative, process-efficient and cost-effective screening tools for protein therapeutics that can be applied to antibody and peptide screens, including all stages of a screening cascade, from primary hybridoma or phage display library screens to lead evaluation functional assays. Yatsula will also discuss the use of endogenous versus recombinant screening cell lines, enabling more physiologically relevant therapeutic models.
Victoria has over 10 years of drug discovery experience that includes small molecule and protein therapeutics research areas. She is the Product Manager at IntelliCyt Corporation where she is involved in the development and marketing of innovative high-throughput cell screening solutions using high speed flow cytometry technology. Prior to IntelliCyt, Victoria was at Bristol-Myers Squibb where as a member of the Cellular Resource Group, she developed and validated multiple stable screening cell lines to support HTS and drug discovery programs in Neuroscience, Virology, Oncology and Metabolic Disease areas. Her expertise includes constitutive, continuous and inducible expression techniques, as well as targeted integration for stable cell line generation. In addition, Victoria managed the flow cytometry core for her department, and it was through those responsibilities that she became aware of High-Throughput Flow Cytometry technology. Before BMS, Victoria was at Bayer Health Care in the Department of Cancer Research where she was focused on high throughput assay development for lead evaluation screens.
Also presenting at the Assay and Drug Discovery Technologies are prestigious organizations including Burnham Medical Research Institute, Pfizer, UCSF, AstraZeneca, UCLA, Bristol Myers Squibb, Genentech, National Institute of Advanced Science and Technology, Johnson & Johnson, Nexigen GmbH, University of Pennsylvania, Roche, UCD, Abbott, Merck, Novartis (GNF), and other leaders in the Assay and Drug Discovery Technologies industry.
5th Assay and Drug Discovery Technologies Conference features a mixture of academic, industry and public sector experts in an intimate setting that favors the showcase of data, the exchanges of ideas and networking. Professionals in the drug discovery industry and academics to can get an update of exciting new developments in assay technologies and exchange ideas in developing creative approaches in the drug discovery and development process to improve the efficiency and output. For more information, visit www.gtcbio.com.
